Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ribo Life Science Closes $40 Million E1 Round for RNA Products

publication date: Jul 29, 2022

Suzhou Ribo Life Science closed a $40 million Series E1 to support global development of its RNA programs. Established in 2007, Ribo focuses on China development of oligonucleotide therapeutics including siRNA, antisense and aptamer drugs based on proprietary intellectual properties. The company has eight products in development, including lead assets for hepatitis B and non-arteritic anterior ischemic optic neuropathy (NAION). It uses conjugated N-acetylgalactosamine (GalNAc) for delivery of many of its products. The E1 financing was backed by Panlin Capital, Trinity Innovation Fund and other investors. More details...,

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital